Patents by Inventor Christopher Dufton

Christopher Dufton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230149354
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Application
    Filed: January 6, 2023
    Publication date: May 18, 2023
    Applicant: ARCA Biopharma, Inc.
    Inventors: Michael BRISTOW, Christopher DUFTON
  • Patent number: 11554107
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 17, 2023
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael Bristow, Christopher Dufton
  • Publication number: 20210251962
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Application
    Filed: February 8, 2021
    Publication date: August 19, 2021
    Applicant: ARCA Biopharma, Inc.
    Inventors: Michael Bristow, Christopher Dufton
  • Patent number: 10925856
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: February 23, 2021
    Assignee: Arca Biopharma, Inc.
    Inventors: Michael Bristow, Christopher Dufton
  • Publication number: 20200268710
    Abstract: The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patientswith heart failure, after being determined to be homozygous Arg389 in the ?1 adrenergic receptor gene.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 27, 2020
    Applicant: ARCA Biopharma, Inc.
    Inventors: Micheal Bristow, Christopher Dufton
  • Patent number: 9993475
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: June 12, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Publication number: 20170136016
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years
    Type: Application
    Filed: November 23, 2016
    Publication date: May 18, 2017
    Applicant: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Patent number: 9504685
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: November 29, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Patent number: 9474752
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: October 25, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Patent number: 9283223
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: March 15, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Publication number: 20150224100
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Inventors: Michael J. Gerber, Christopher Dufton
  • Publication number: 20140296244
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Application
    Filed: February 17, 2014
    Publication date: October 2, 2014
    Inventors: Michael J. Gerber, Christopher Dufton
  • Patent number: 8377933
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 19, 2013
    Assignee: Gilead Colorado, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Publication number: 20110245253
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Application
    Filed: June 16, 2011
    Publication date: October 6, 2011
    Inventors: Michael J. Gerber, Christopher Dufton
  • Publication number: 20100152217
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 17, 2010
    Inventors: Michael J. Gerber, Christopher Dufton
  • Publication number: 20080139593
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Application
    Filed: December 11, 2007
    Publication date: June 12, 2008
    Inventors: Michael J. Gerber, Christopher Dufton